A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

This invention relates to extracts rich in N-acids of imino sugars (as opposed to neutral and basic imino sugars) and/or pipecolic acids obtainable from the plant leaves of mulberry (Morus). The extracts have been shown to have enzymatic activities making extracts rich in these compounds, and the compounds isolated from these extracts, to be good candidates for use in the treatment of diseases, particularly, but not exclusively, metabolic disorders, such as, for example, diabetes.

Disclosed is the use of a DKK1 gene or the coded protein inhibitor thereof for the preparation of a composition or formulation used to prevent and/or treat tumor cachexia and diseases associated with diabetes. By inhibiting the expression or activity of the DKK1 gene or the protein encoded thereby in tumor cells, which can effectively prevent and/or treat tumor cachexia and diseases associated with diabetes, also provided is a method for detecting the protein expression level of DKK1 in blood, which level is taken as an indicator for precise treatment and judging prognosis.

Disclosed herein are combinational therapies for diabetes comprising a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs and a second effective amount of one or more second active ingredients selected from the group consisting of insulin and insulin analogs.

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.

2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof are provided. Specifically, the 2-aminopyrimidine compounds have a structure as shown in formula I. The compounds are suitable for use in the fields of anti-virus and anti-infection, as well as treatment of diseases such as autoimmune diseases and tumors.

##STR00001##

Pharmaceuticals compositions comprising the 2S,4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R,4S ketoconazole enantiomer are useful to reduce cortisol synthesis and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.

The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.